Investigational drug · Phase 3
TQB2868
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Neoplasms, Metastatic Pancreatic Ductal Adenocarcinoma.
Phase 3Last checked: Nov 20, 2026Latest source record: May 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
8
Any phase or sponsor naming "TQB2868"
First trial start
2024
Mar 19, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQB2868", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Neoplasms
- Metastatic Pancreatic Ductal Adenocarcinoma
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "TQB2868" as an intervention, largest first.
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)Pivotal-lookingRecruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT07165951 · 566 participants (planned) · Start Dec 2, 2025 · Primary completion May 2028
Drug: TQB2868 Injection; Anlotinib Hydrochloride Capsules and 3 more · For: Metastatic Pancreatic Ductal Adenocarcinoma
Sites: Hefei, China; Beijing, China; Chongqing, China · 71 sites in all
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT05198505 · 280 participants (planned) · Start Apr 27, 2022 · Primary completion Jun 2023
Drug: TQB2868 Injection · For: Advanced Malignant Tumor
Sites: Zhengzhou, China; Linyi, China; Shanghai, China
Fudan UniversityAcademic, hospital or other
NCT05749588 · 120 participants (planned) · Start Mar 30, 2023 · Primary completion Dec 31, 2027
Drug: A1: SHR-A1811; A2: SHR-A1811 with Camrelizumab with famitinib and 12 more · For: Triple-negative Breast Cancer
Sites: Shanghai, China
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06767813 · 80 participants (planned) · Start Mar 19, 2024 · Primary completion Nov 2026
Drug: TQB2868 injection; Gemcitabine injection and 2 more · For: Pancreatic Neoplasms
Sites: Zhengzhou, China; Nanjing, China; Suzhou, China · 7 sites in all
- Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic CholangiocarcinomaNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07846267 · 56 participants (planned) · Start Oct 1, 2026 · Primary completion Oct 1, 2029
Drug: Anlotinib; TQB2868 Injection · For: Intrahepatic Cholangiocarcinoma
Sites: Shanghai, China
Fudan UniversityAcademic, hospital or other
NCT06441019 · 42 participants (planned) · Start Jul 1, 2024 · Primary completion May 31, 2025
Drug: HAIC(Oxaliplatin+ Raltitrexed)、TQB2868、Ramucirumab · For: Hepatocellular Carcinoma,Bispecific Antibodies, HAIC, Ramucirumab
Sites: Shanghai, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05998941 · 0 participants · Start Aug 2023 · Primary completion Feb 2025
Drug: TQB2868 injection; Paclitaxel injection and 3 more · For: Cervical Cancer
Sites: Chongqing, China; Fuzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Pancreatic Neoplasms
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- BrigimadlinBI 907828Phase 33 trials
Boehringer Ingelheim · Solid Tumours, Pancreatic Neoplasms, Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.